

CV of Wenhui LOU

1. General Information

Name: Wenhui Lou M.D.

Title: Professor of Surgery

Address: Department of Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, P.R.China

E-mail: lou.wenhui@zs-hospital.sh.cn

Tel: 86-13681971683

2. Education

(1) Sep. 1986-July 1992: Shanghai Medical University, Bachelor of Medicine

(2) Sep. 1994-June 1996: Graduate School, Shanghai Medical University, Master of Medicine

(3) Sep. 1996-July 1999: Graduate School, Shanghai Medical University, Doctor of Medicine

3. Employment

(1) July 1992-May 1995: Resident, Department of Surgery, Zhongshan Hospital, Shanghai Medical University

(2) June 1995-May 1996: Chief Resident, Department of Surgery, Zhongshan Hospital, Shanghai Medical University.

(3) June 1996-Oct. 2001: Attending Surgeon, Department of Surgery, Zhongshan Hospital, Shanghai Medical University

(4) Nov. 2001- Nov 2009: Associate Professor, Department of Surgery, Zhongshan Hospital, Fudan University

(5) Nov 2009-Now: Professor of Surgery, Department of Surgery, Zhongshan Hospital, Fudan University

(6) May 2011-Now: Vice-Chair, Department of Surgery, Zhongshan Hospital, Fudan University

(7) June 2012-Now: Chair, Department of Pancreatic Surgery, Zhongshan Hospital, Fudan University

(8) May 2011-Now: Director, Surgical Lab, Zhongshan Hospital, Fudan University

4. Professional Societies

(1) Fellow, National Surgical Committee of China.

(2) Fellow of Chinese College of Surgeon

(3) Vice-Chair, Chinese Society of Pancreatology

(4) Vice Chair, Chinese Neuroendocrine Society

(5) Chair , Shanghai Surgical Association

(6) Vice-Chair, National Pancreatic Surgical Association of China

(7) Member of Editorial Board, 《Journal of Digestive Disease》

(8) Member of Editorial Board, 《Annual of Surgery》 (Chinese Version)

5. Publication (Only English publication in past 5 years be listed)

1. Yefei Rong, Wenchuan Wu, Xiaoling Ni, Tiantao Kuang, Dayong Jin, Dansong Wang, **Wen-Hui Lou (Corresponding Author)**. Lactate dehydrogenase A is overexpressed in pancreatic cancer and promote the growth of pancreatic cells. Tumor Biol, 2013(34):1523-1530
2. Wen Chuan WU, Xiu Zhong YAO, Da Yong JIN, Dan Song WANG, **Wen Hui LOU(Corresponding Author)** & Xin Yu. Clinical strategies for identifying autoimmune pancreatitis from pancreaticobiliary malignancy to avoid unnecessary surgical resection. Journal of Digestive Disease. 2013, 14(9):500-508
3. Xu B, Ding WX, Jin DY, Wang DS, **Lou WH (Corresponding Author)**. Decision making for pancreatic resection in patients with intraductal papillary mucinous neoplasms. World J



- Gastroenterol. 2013 Mar 7;19(9):1451-7
4. Han X, Zhao J, Ji Y, Xu X, **Lou W (Corresponding Author)**. Expression of CK19 and KIT in resectable pancreatic neuroendocrine tumors. *Tumor Biol*, 2013(34):
 5. Han X, Ji Y, Zhao J, Xu X, **Lou W (Corresponding Author)**. Expression of PTEN and mTOR in pancreatic neuroendocrine tumors. *Tumor Biol*, 2013 Oct;34(5):2871-9
 6. Chen-Ye Shi, Yue Fan, Bin Liu, **Wen-Hui Lou (Corresponding Author)**. HIF1 promotes QSOX1 expression contributes to hypoxia-induced pancreatic cancer cells invasion. *Cell physiol biochem*. 2013 , 32 (3) : 561-8
 7. Han X, Jin Zhao, Yuan Ji, **Lou W (Corresponding Author)**. Clinicopathological characteristics and prognosis-related factors of resectable pancreatic neuroendocrine tumors: a retrospective study of 104 cases in a single Chinese center. *Pancreas* 2014 May;43(4):526-31
 8. Wenchuan Wu, Xiuzhong Yao, Chao Lin, Dayong Jin, Dansong Wang, **Wenhui Lou (Corresponding Author)**, and Xinyu Qin. Should Steroid Therapy Be Necessarily Needed for Autoimmune Pancreatitis Patients with Lesion Resected due to Misdiagnosed or Suspected Malignancy? *Gastroenterology Research and Practice*, 2014, Article ID 253471, 6 pages
 9. Xue-Feng X, Jian-Ang L, **Wen-Hui L (Corresponding Author)**. The impact of internal stenting of pancreatojejunostomy on the pancreatic fistula rate after pancreaticoduodenectomy. *Am Surg*. 2014 Feb; 80(2):215-6.
 10. Xu Xuefeng, Li Jian'ang, Han Xu, Shi Chenye, Jin Dayong and **Lou Wenhui (Corresponding Author)**. Clinical characteristics and prognostic factors of patients with gastric neuroendocrine carcinoma treated with radical surgery. *Chinese Medical Journal* 2014;127 (13) : 2419
 11. Yefei Rong, Dansong Wang, Wenchuan Wu, Dayong Jin, Tiantao Kuang, Xiaolin Ni, Lei Zhang, **Wen-Hui Lou (Corresponding Author)**. TRAF6 is over-expressed in pancreatic cancer and promotes the tumorigenicity of pancreatic cancer cells. *Med Oncol.*, 2014,31:260
 12. Fang Y, Chai Z, Wang D, Kuang T, Wu W, **Lou W (Corresponding Author)**. DNA-PKcs deficiency sensitizes the human hepatoma HepG2 cells to cisplatin and 5-fluorouracil through suppression of the PI3K/Akt/NF- κ B pathway. *Mol Cell Biochem* (2015) 399:269–278 (IF 2.38)
 13. Hexige S1, Ardito-Abraham CM, Wu Y, Wei Y, Fang Y, Han X, Li J, Zhou P, Yi Q, Maitra A, Liu JO, Tuveson DA, **Lou W (Corresponding Author)** Yu L. Identification of novel vascular projections with cellular trafficking abilities on the microvasculature of pancreatic ductal adenocarcinoma. *J Pathol*. 2015;236(2):142-54 (IF 7.33)
 14. Xu Han, Chunyan Zhang, Min Tang, Xuefeng Xua, Lingxiao Liud, Yuan Jie, Baishen Pan and **Wenhui Lou (Corresponding Author)**. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases. *European Journal of Gastroenterology & Hepatology* 2015, 27:527–535 (IF 2.38)
 15. Fang Y, Saiyin H, Zhao X, Wu Y, Han X, Lou WH (**Corresponding Author**). IL-8-Positive Tumor-Infiltrating Inflammatory Cells Are a Novel Prognostic Marker in Pancreatic Ductal Adenocarcinoma Patients. *Pancreas*. 2016 May-Jun;45(5):671-8
 16. Li JA, Xu XF, Han X, Fang Y, Shi CY, Jin DY, Lou WH (**Corresponding Author**). Nab-Paclitaxel Plus S-1 Shows Increased Antitumor Activity in Patient-Derived Pancreatic Cancer Xenograft Mouse Models. *Pancreas*. 2016 Mar;45(3):425-33 (IF 3.0)
 17. Liu T, Fang Y, Zhang H, Deng M, Gao B, Niu N4 Yu J, Lee S, Kim J, Qin B, Xie F, Evans D, Wang L, Lou W (**Corresponding Author**), Lou Z. HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy. *Cancer Res*. 2016 Feb 1;76(3):572-81 (IF 9.3)
 18. Chao Lin, Guo-chao Zhao, Ya-dong Xu, Dan-song Wang, Da-yong Jin, Yuan Ji, **Wen-hui Lou (Corresponding Author)**, Wen-chuan Wu. Increased expression of α Tubulin is associated with poor prognosis in patients with pancreatic cancer after surgical resection. *Oncotarget*, 2016 Sep 13;7(37):60657-60664
 19. Peng Yuan, Xiao-Hong He, Ye-Fei Rong, Jing Cao, Yong Li, Yun-Ping Hu, Yingbin Liu,



- Dangsheng Li, **Wenhui Lou (Corresponding Author)** & Mo-Fang Liu. KRAS-NFκB-YY1-miR-489 signaling axis controls pancreatic cancer metastasis. *Cancer Research* 2017 Jan 1;77(1):100-111 (IF 9.3)
20. Wentao Zhou, Yadong Xu, Yefei Rong, Wenchuan Wu, Tiantao Kuang, Baobao Xin, Hongxu Zhu, **Wenhui Lou (Corresponding Author)**, Dansong Wang. Validation of Sendai and Fukuoka consensus guidelines in predicting malignancy in patients with preoperatively diagnosed mucinous pancreatic cystic neoplasms. *J Surg Oncol.* 2017;1-8. (IF 2.99)
 21. Hexige Saiyin1, Ning Na2, Xu Han, Yuan Fang, Yanhua Wu, **Wenhui Lou (Corresponding Author)** and Xianmei Yang. BRSK2 induced by nutrient deprivation promotes Akt activity in pancreatic cancer via downregulation of mTOR activity. *Oncotarget*, 2018 (**ahead of publication**)
 22. Jian-ang Li, Chao Song, Yefei Rong, Tiantao Kuang, Dansong Wang, Xuefeng, Xu, Jian Yuan, Kuntian Luo, Bo Qin, Somaira Nowsheen, Zhenkun Lou & Wenhui Lou (Corresponding Author). Chk1 inhibitor SCH 900776 enhances the antitumor activity of MLN4924 on pancreatic cancer. *Cell Cycle* 2018 (**ahead of publication**)
 23. Ning Pu, YangLv, Guochao Zhao, Wanling Lee, Abulimiti Nuerxiati, Dansong Wang, Xuefeng Xu, Tiantao Kuang, Wenchuan Wu, **Wenhui Lou (Corresponding Author)**. Survival prediction in pancreatic cancer patients with no distant metastasis: a large-scale population-based estimate. *Future Oncology*, 2018 (**ahead of publication**)
 24. Yang Lv, Cheng Huang, Haizhou Xu, Xu Han, Lei Zhang, Weilin Mao, Yuan Ji, Dayong Jin, **Wenhui Lou (Corresponding Author)**, Xuefeng Xu. Clinicopathological Characteristics of the primary and metastatic Hepatic Neuroendocrine Tumors and the relevant Prognosis-Related Factors: A Retrospective Study of 81 Cases in a Single Chinese Center. *Journal of Cancer*, 2018; 9(3): 479-487. (IF 2.91)
 25. Yang Lv, Xu Han1, Chunyan Zhang, Yuan Fang, Ning Pu, Yuan Ji, Dansong Wang, Xuefeng Xu and **Wenhui Lou (Corresponding Author)**. Combined test of serum CgA and NSE improved the power of prognosis prediction of NF-pNETs. *Endocrine Connections* (2018) 7, 1-11(IF 2.54)
 26. Pu N, Li JA, Xu YL, Lee WL, Fang Y, Han X, Zhao GC, Zhang L, Nuerxiati A, Yin HL, Wu WC, Lou WH (Corresponding Author). Comparison of prognostic prediction between nomogram based on lymph node ratio and AJCC 8th staging system for patients with resected pancreatic head carcinoma: a SEER analysis. *Cancer Management and Research* 2018;10 227-238 (IF 3.8)
 27. Yuan Fang, Xu Hana, Lingxiao Liub,, Wenhui Lou Lou WH (Corresponding Author). Diagnosis and treatment efficacy of digital subtraction angiography and transcatheter arterial embolization in post-pancreatectomy hemorrhage: A single center retrospective cohort study. *International Journal of Surgery* 51 (2018) 223-228 (IF 2.0)
 28. Wenhui Lou, Ying Xia, Peng Xiang, Liangqing Zhang, Xiangyou Yu, Sam Lim, Mo Xu, Lina Zhao, Hans Rydholm, Barry Traxler & Xinyu Qin. Prevention of upper gastrointestinal bleeding in critically ill Chinese patients: a randomized, double-blind study evaluating esomeprazole and cimetidine. *Current Medical Research and Opinion*, 2018 Aug;34(8):1449-1455 (IF 2.75)
 29. Yaolin Xu, Xi Guo2, Yue Fan, Dansong Wang, Wenchuan Wu, Lili Wu4, Tianshu Liu, Bei Xu, Yi Feng, Yan Wang, Wenhui Lou (Corresponding Author) and Yuhong Zhou. Efficacy and safety comparison of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line chemotherapy for metastatic pancreatic cancer. *Japanese Journal of Clinical Oncology*, 2018, 1-7 (IF 2.0)
 30. Gao S, Pu N, Liu L, Li C, Xu X, Wang X1 Lou W (Corresponding Author). The latest exploration of staging and prognostic classification for pancreatic neuroendocrine tumors: a large population-based study. *J Cancer* 2018 Apr 19;9(9):1698-1706 (IF 3.249)..
 31. Han X, Xu X, Ma H, Ji Y, Wang D, Kuang T, Wu W, Song B, Li G, Jin G, Lou W (Corresponding Author). Clinical relevance of different WHO grade 3 pancreatic neuroendocrine neoplasms based on morphology. *Endocr Connect.* 2018 Feb;7(2): 355-363 (IF 2.54)
 32. Lv Y, Huang C, Xu H, Han X, Zhang L, Mao W, Ji Y, Jin D, Lou W (Corresponding Author) ,



HBP SURGERY WEEK 2019

& The 50th Annual congress of the
Korean Association of HBP Surgery

APRIL 5 - 6, 2019 GRAND HILTON SEOUL, KOREA
www.khbps.org



Xu X. Clinicopathological Characteristics of the primary and metastatic Hepatic Neuroendocrine Tumors and the relevant Prognosis-Related Factors: A Retrospective Study of 81 Cases in a Single Chinese Center. J Cancer. 2018 Jan 1;9(3):479-487. (IF 3.249).